OREX Financial Facts
Research and development: 5.25MInterest income: 239K
See Full Income Statement
Cash and cash equivalents: 74.43M
Total stockholders' equity: 73.42M
See Full Balance Sheet
Orexigen Therapeutics (OREX) Earnings
|
Expand Research on OREX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +31.4% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -22.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/9/17 |  |
Q117 | -$4.67 | N/A | N/A | $19.1M | $20M | = |  | | Details |
| 8/8/17 | |
Q217 | -$2.00 | N/A | N/A | $23.4M | $19.14M | = | | | Details |
8/4/16  |
|
Q216 | -$1.73 | -$1.47 | -$0.26 | $7.8M | $6.88M | N/A | | | Details |
| 3/28/17 |
|
Q416 | -$1.69 | -$1.18 | -$0.51 | $13.88M | $13.95M | N/A | | | Details |
| 11/13/17 | |
Q317 | -$1.35 | -$2.13 | +$0.78 | $18.9M | $24.2M | = | | | Details |
| 11/7/12 |
|
Q312 | -$0.44 | -$0.30 | -$0.14 | $857K | $890K | N/A | | | Details |
| 3/13/13 | Q412 | -$0.41 | -$0.44 | +$0.03 | $857K | $910K | N/A | | | Details | |
| 8/7/12 | Q212 | -$0.25 | -$0.17 | -$0.08 | $857K | $890K | N/A | | | Details |
